Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: ResApp Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) completes the recruitment ahead of schedule for its Indian COVID-19 clinical study
  • A total of 100 COVID-19 positive patients have been recruited and given the fast recruitment, the trial has been expanded to 200 positive cases
  • This increase will enable a greater range and certainty of results, giving ResApp the highest chance of developing an accurate COVID-19 screening device
  • ResApp will use the data from the trial to aid in the development of its smartphone-based algorithm that screens for COVID-19 and monitors disease progression
  • Shares in ResApp are up 1.56 per cent on the market and are trading at 6.5 cents

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.

In early August, the mobile healthcare company hired clinical trial company Triomics to begin recruiting COVID-19 positive and negative patients in India.

A total of 100 COVID-19 positive patients have been recruited and given the fast recruitment, the trial has been expanded to 200 positive cases with all expected to be recruited by the end of November.

This increase will enable a greater range of results and certainty of evaluating COVID-19 screening protocols, giving ResApp the highest chance of developing an accurate COVID-19 screening device.

Additionally, ResApp is recruiting patients for two US clinical studies, with enrolment expected to be complete in mid-December.

ResApp will use the data from both trials to aid in the development of its smartphone-based algorithm that screens for COVID-19 and monitors disease progression.

CEO and Managing Director Tony Keating is pleased recruitment has reached its target ahead of time.

“We are pleased to have reached our initial target recruitment for COVID-19 positive cases in India ahead of time,” Dr Keating commented.

“We now commence the important work of analysing the data collected in India and the US, and performing specific algorithm training and validation to build on the foundational algorithm work we’ve undertaken over the past few months.

“The development of an instant smartphone-based screening test for COVID-19 could revolutionise the way the world manages the virus.”

Shares in ResApp were up 1.56 per cent on the market and were trading at 6.5 cents at 11:33 am AEDT.

RAP by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.